Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk HCQ for COVID-19  Ashraf et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 100 patients in Iran Lower mortality with HCQ (not stat. sig., p=0.15) c19hcq.org Ashraf et al., medRxiv doi:10.1101/202.., Apr 2020 Favors HCQ Favors control

COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes

Ashraf et al., medRxiv doi:10.1101/2020.04.20.20072421.t
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Small limited trial with 100 patients concluding that HCQ improved clinical outcome, OR 0.016 [0.002-0.11] in regression analysis.
risk of death, 67.5% lower, RR 0.32, p = 0.15, treatment 10 of 77 (13.0%), control 2 of 5 (40.0%), NNT 3.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ashraf et al., 24 Apr 2020, retrospective, database analysis, Iran, preprint, median age 58.0, 16 authors, dosage 200mg bid daily, 400mg qd was used when combined with Lopinavir-Ritonavir.
This PaperHCQAll
COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Mohammad Ali Ashraf, Nasim Shokouhi, Elham Shirali, Fateme Davari-Tanha, Omeed Memar, Alireza Kamalipour, Ayein Azarnoush, Avin Mabadi, Adele Ossareh, Milad Sanginabadi, Talat Mokhtari Azad, Leila Aghaghazvini, Sara Ghaderkhani, Tahereh Poordast, Alieh Pourdast, Pershang Nazemi
doi:10.21203/rs.3.rs-26339/v1
Background There is a growing need for information regarding the recent coronavirus disease of 2019 . We present a comprehensive report of Covid-19 patients in Iran. Methods One hundred hospitalized patients with Covid-19 were studied. Data on potential source of exposure, demographic, clinical, and paraclinical features, therapy outcome, and post-discharge follow-up were analyzed. Results The median age of the patients was 58 years, and the majority of the patients (72.7%) were above 50 years of age. Fever was present in 45.2% of the patients on admission. The most common clinical symptoms were shortness of breath (74%) and cough (68%). Most patients had elevated Creactive protein (92.3%), elevated erythrocyte sedimentation rate (82.9%), lymphocytopenia (74.2 %) on admission. Lower lobes of the lung were most commonly involved, and ground-glass opacity (81.8%) was the most frequent finding in CT scans. The administration of hydroxychloroquine improved the clinical outcome of the patients. Lopinavir/ritonavir was efficacious at younger ages. Of the 70 discharged patients, 40% had symptom relapse, (8.6%) were readmitted to the hospital, and 3 patients (4.3%) died. Conclusions This report demonstrates a heterogeneous nature of clinical manifestations in patients affected with Covid-19. The most common presenting symptoms are non-specific, so attention should be made on broader testing, especially in age groups with the greatest risk and younger individuals who can serve as carriers of the disease. Hydroxychloroquine and lopinavir/ritonavir (in younger age group) can be potential treatment options. Finally, patients discharged from the hospital should be followed up because of potential symptom relapse.
Competing interests. The authors declare that they have no competing interests. Authors' contributions. MS and LA interpreted the data regarding radiologic findings in this study. SA, TP, AP, and PN made substantial contributions in the designing and the concept of the study. AA, AM, and AS had contribution in acquisition and analysis of the data. TMA had a role in writing the manuscript and interpretation the data regarding the PCR confirmation of the patients. MA had major contribution in interpretation of data and writing the main manuscript. OM and AK had substantially revised the manuscript. NS, ES, FD had major roles in acquisition and interpretation regarding lab findings and post-discharge follow-up data. Every author thoroughly read the entire manuscript and checked for the accuracy of the data, protocol method, and analysis. mild, moderate, and severe disease was as below according to the national guideline: Patients with a flu-like syndrome with/without fever, who did not have any signs of infiltration in lung imaging were classified as having mild disease. The moderate group was defined as symptomatic patients with pulmonary infiltration or at least one of the admission criteria, as explained in the figure. The severe group constituted patients who have at least one of the following criteria: 1. Reduced consciousness; 2. Respiratory rate (RR) ≥30; 3. Blood pressure (BP)BP<90/60; 4. Multi lobular infiltration; 5. Hypoxemia. Supplementary Files
References
Arabi, Balkhy, Hayden, Bouchama, Luke et al., Middle East Respiratory Syndrome New England, Journal of Medicine
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet
Cheng, Luo, Wang, Zhang, Wang et al., Kidney impairment is associated with in-hospital death of COVID-19 patients, doi:10.1101/2020.02.18.20023242
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance
Gao, Tian, Yang, Breakthrough. Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, BioScience Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Greenberg, Update on Human Rhinovirus and Coronavirus Infections, Seminars in Respiratory Critical Care Medicine
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Ksiazek, Erdman, Goldsmith, Zaki, Peret et al., A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome, N Engl J Med
Lan, Xu, Ye, Xia, Wang et al., Positive RT-PCR Test Results in Patients Recovered From COVID-19, JAMA
Li, Wu, Wu, Guo, Chen et al., The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia, Invest Radiol, doi:10.1097/rli.0000000000000672
Lipsitch, Swerdlow, Finelli, Defining the Epidemiology of Covid-19 -Studies Needed, N Engl J Med
Mao, Wang, Chen, He, Chang et al., a retrospective case series study, doi:10.1101/2020.02.22.20026500
Tabrizi, Lankarani, Nowrouzi-Sohrabi, Shabani-Borujeni, Rezaei et al., The role of comorbidities and clinical predictors of severe disease in COVID-19: a systematic review and meta-analysis, doi:10.1101/2020.04.21.20074633
Tuite, Bogoch, Sherbo, Watts, Fisman et al., Estimation of Coronavirus Disease 2019 (COVID-19) Burden and Potential for International Dissemination of Infection From Iran, Ann Intern Med, doi:10.7326/m20-0696
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA
Xu, Dong, Lv, Yin, Zhang, Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2, J Infect
Zhang, Yan, Ye, Lin, Zheng et al., SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.03.007
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective study, The Lancet
Zhuang, Zhao, Lin, Cao, Lou et al., Preliminary estimation of the novel coronavirus disease (COVID-19) cases in Iran: A modelling analysis based on overseas cases and air travel data, International Journal of Infectious Diseases
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit